Skip to main content
Fig. 3 | The Journal of Headache and Pain

Fig. 3

From: Relative efficacy of lasmiditan versus rimegepant and ubrogepant as acute treatments for migraine: network meta-analysis findings

Fig. 3

NMA results for pain freedom at 2 hours. aSensitivity analysis 2 analysed rimegepant according to its mode of administration (tablet or ODT). Pairwise treatment comparisons – results from Bayesian fixed-effects NMA adjusted for baseline risk (base case analysis: 36 observations, residual deviance = 36.26 [adjusted baseline risk: mean -0.54 (95% Crl -0.73, -0.28)]; sensitivity analysis 2: 36 observations, residual deviance = 35.74 [adjusted baseline risk: mean -0.52 (95% Crl -0.71, -0.25)]). Crl, credible interval; NMA, network meta-analysis; ODT, oral disintegrating tablet; OR, odds ratio

Back to article page

The Journal of Headache and Pain

ISSN: 1129-2377

Contact us